ERG and prostate cancer: ERG activation/overexpression is mainly due to fusion with regulatory sequences of the androgen receptor related prostate cancer genes, predominantly TMPRSS2. The TMPRSS2-ERG fusion is a well-known PCa driver alteration [13].